Nov 12, 2015· Comment from National Association of Chain Drug Stores (NACDS)· FDA-2015-N-0648-0051
See the attached comments of the National Association of Chain Drug Stores on the FDA proposed rule to designate official names and proper names for certain biological products (Docket No. FDA-2015-N-0648.) FDA's naming policies for biological and biosimilar drugs are of critical importance to the chain pharmacy community, as these policies will have significant patient safety implications. As such, we appreciate FDA considering our comments on this important policy matter.